Latest revenue
$106.5K
as of 2026-03-31
Latest net income
$-151.4K
as of 2026-03-31
Net margin
-142.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $24.6M
- Enterprise value
- $24.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.90
- 52-wk low
- $0.11
- Beta
- —
- Shares out
- 49.1M
5-year trend
What this company does
ITEM 1. BUSINESS. Global Innovative Platforms Inc. f/k/a Canning Street Corporation, a Delaware corporation, (“Global Innovative Platforms”,” Canning Street,” the “Company”, “we,” “us” or “our”) is engaged in the business of testing breath to detect and assist in the treatment of disease. Our Current Business Global Innovative Platforms is focused on advancing animal health through breath analysis and air quality technology. We develop non-invasive diagnostic tools for detecting diseases, assessing treatment effectiveness. Our proprietary technologies, “VOCAM Plus” and the “FROG,” utilize advanced gas chromatography and A.I. software to provide rapid and accurate breath and air analysis.…
AI summary unavailable — showing raw filing excerpt
Generated from GIPL's filing dated 2026-01-13
Key risks
ITEM 1A. RISK FACTORS. The following risk factors and other information included in this Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the events or circumstances described in the following risk factors actually occurs, our business, operating results and financial condition could be materially adversely affected. Our plan of operation is to obtain debt or equity financing to meet our ongoing operating expenses and attempt to develop our operations and…
AI summary unavailable — showing raw filing excerpt
Generated from GIPL's filing dated 2026-01-13
Profitability
Return on equity
-382.7%
193.1%Return on assets
-360.4%
100.0%Leverage
Debt / equity
0.06×
106.2%Debt / assets
5.8%
100.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $106.5K | — | $-151.4K | -0.0% | -142.1% |
Q4 2025 2025-12-31 | $30.0K | — | $-49.4K | +59.0% | -164.8% |
Q3 2025 2025-09-30 | — | — | $-234.6K | -206.8% | — |
Q2 2025 2025-06-30 | — | — | $-211.8K | -3230.5% | — |
Q1 2025 2025-03-31 | $0 | — | $-151.4K | -3793.8% | — |
Q4 2024 2024-12-31 | — | — | $-120.5K | -143.5% | — |
Q3 2024 2024-09-30 | $0 | — | $-76.5K | — | — |
Q2 2024 2024-06-30 | $0 | — | $-6.4K | -140.0% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on GIPL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.9K
Insider selling
$0
Net activity
+$1.9K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GIPL
No institutional holdings on file for GIPL yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once GIPL's latest filing finishes processing.